IL-4, TGF-?, NF-?B and MPO levels in Patients with Treatment Resistant Schizophrenia

Basit Öğe Kaydı
dc.authoridZayman, Esra Porgalı/0000-0003-1551-6782
dc.authoriderbay, lale gönenir/0000-0002-9969-3016
dc.authoridkartalcı, şükrü/0000-0003-2560-0355
dc.authoridOtlu, Onder/0000-0001-5958-7609
dc.authoridKARTALCI, GÜLŞEN/0000-0002-7276-6174
dc.authorwosidZayman, Esra Porgalı/ABI-2950-2020
dc.authorwosiderbay, lale gönenir/AAE-6285-2019
dc.authorwosidkartalcı, şükrü/ABI-1106-2020
dc.authorwosidOtlu, Onder/W-3887-2018
dc.authorwosidKARTALCI, GÜLŞEN/ABI-1956-2020
dc.contributor.authorKartalci, Sukru
dc.contributor.authorErbay, Lale Gonenir
dc.contributor.authorZayman, Esra Porgali
dc.contributor.authorOtlu, Onder
dc.contributor.authorKarabulut, Aysun Bay
dc.contributor.authorKartalci, Gulsen
dc.date.accessioned2024-08-04T20:42:47Z
dc.date.available2024-08-04T20:42:47Z
dc.date.issued2016
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjective: Schizophrenia is a chronic psychotic disorder in which genetics and environmental factors such as infection and the corresponding immune response play a role in the etiopathogenesis. The aim of this study was to compare some immune factors such as nuclear factor-kappa B (NF-kappa B) activation, myeloperoxidase (MPO), the anti-inflammatory cytokine interleukin-4 (IL-4), and regulatory cytokine transforming growth factor-beta (TGF-beta) in schizophrenia patients and an age- and gender-matched control group. Method: Plasma levels of IL-4, TGF-beta, MPO, and NF-kappa B activation in 20 subjects with treatment-resistant schizophrenia and 20 age- and gender-matched healthy controls were analyzed. Disease severity was evaluated using the Brief Psychiatric Rating Scale (BPRS). Results: Plasma TGF-beta levels were found to be significantly lower and NF-kappa B to be significantly higher in antipsychotic treatment-resistant schizophrenia patients than in controls in this study. No significant differences were found between the patient and control groups for serum IL-4 and MPO levels. Conclusion: The low TGF-beta level in treatment-resistant schizophrenia patients in the symptom exacerbation period indicates that there is inadequate Th1/Th2 balance. Large-scale studies are required to investigate whether this is responsible for resistance in schizophrenia. The fact that the increase in NF-kappa B that we found in treatment resistant schizophrenia patients in this study has also been reported in the first attack in untreated schizophrenia patients in previous studies indicates that NF-kappa B plays a role in the disorder's physiopathology from the beginning.en_US
dc.identifier.doi10.5080/u13642
dc.identifier.endpage175en_US
dc.identifier.issn1300-2163
dc.identifier.issue3en_US
dc.identifier.pmid27711937en_US
dc.identifier.scopus2-s2.0-84995686647en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage170en_US
dc.identifier.urihttps://doi.org/10.5080/u13642
dc.identifier.urihttps://hdl.handle.net/11616/97586
dc.identifier.volume27en_US
dc.identifier.wosWOS:000384785400004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isotren_US
dc.publisherTurkiye Sinir Ve Ruh Sagligi Dernegien_US
dc.relation.ispartofTurk Psikiyatri Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSchizophreniaen_US
dc.subjectIL-4en_US
dc.subjectTGF-betaen_US
dc.subjectNF-kappa Ben_US
dc.subjectmyeloperoxidaseen_US
dc.titleIL-4, TGF-?, NF-?B and MPO levels in Patients with Treatment Resistant Schizophreniaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu